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Purpose: The aim of this study was to assess the effect of applying ACR Lung-RADS in a clinical CT lung screening program on the
frequency of positive and false-negative ﬁndings.
Methods: Consecutive, clinical CT lung screening examinations performed from January 2012 through May 2014 were retroactively
reclassiﬁed using the new ACR Lung-RADS structured reporting system. All examinations had initially been interpreted by radiologists
credentialed in structured CT lung screening reporting following the National Comprehensive Cancer Network’s Clinical Practice Guidelines in
Oncology: Lung Cancer Screening (version 1.2012), which incorporated positive thresholds modeled after those in the National Lung Screening
Trial. The positive rate, number of false-negative ﬁndings, and positive predictive value were recalculated using the ACR Lung-RADS-speciﬁc
positive solid/part-solid nodule diameter threshold of 6 mm and nonsolid (ground-glass) threshold of 2 cm. False negatives were deﬁned as cases
reclassiﬁed as benign under ACR Lung-RADS that were diagnosed with malignancies within 12 months of the baseline examination.
Results: A total of 2,180 high-risk patients underwent baseline CT lung screening during the study interval; no clinical follow-up was
available in 577 patients (26%). ACR Lung-RADS reduced the overall positive rate from 27.6% to 10.6%. No false negatives were
present in the 152 patients with >12-month follow-up reclassiﬁed as benign. Applying ACR Lung-RADS increased the positive
predictive value for diagnosed malignancy in 1,603 patients with follow-up from 6.9% to 17.3%.
Conclusions: The application of ACR Lung-RADS increased the positive predictive value in our CT lung screening cohort by a factor
of 2.5, to 17.3%, without increasing the number of examinations with false-negative results.
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The National Lung Screening Trial (NLST) demonstrated that
CT lung screening reduces lung cancerespeciﬁc mortality in
high-risk patients when the minimum size of a positive pul-
monary nodule is set at 4 mm [1]. Because more than half of
baseline examinations in the NLST were positive for nodules 4
to 6 mm in size, raising the threshold for a positive result to 6mm
would decrease the baseline NLST positive rate from 27.3% to
approximately 13.4% [1]. Given the 0.5% positive predictive
value (PPV) in the NLST of an examination positive for a nodule
measuring4 to6mm, increasing the threshold of positiveCT lung
screening results to 6mmhas the potential to increase the PPV byaDepartment of Radiology, Lahey Hospital & Medical Center, Burlington,
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Open access under CC BY-NC-ND license.a factor of 1.8 (7.2% at 6 mm vs 3.8% at 4 mm) without
signiﬁcantly affecting the sensitivity to detect malignancy [1].
The International Early LungCancer Action Program reported
an analogous observation: a reduction in baseline positive results to
10.2% at a 6-mm solid nodule threshold compared with 16% at a
5-mm threshold. Notably, the same number of lung cancers was
detected within 12 months at both thresholds [2].
After publication of these International Early Lung Cancer
Action Program ﬁndings, both the National Comprehensive
Cancer Network (NCCN) and the ACR adopted 6 mm as the
minimum nodule-size threshold for positive CT lung screening
results [3,4]. To further decrease the frequency of false-positive
CT lung screening results, ACR Lung-RADS version 1.0 set
the size of a positive nonsolid (ground-glass) nodule to 2 cm and
the durationof nodule stability required tomeet criteria for benign
behavior to 3 months, compared with 2 years in the NLST [4].
In this study, we retroactively applied the ACR Lung-RADS
positive nodule-size thresholds to our clinical CT lung screening
results. These had originally been interpreted using the
NCCN Clinical Practice Guidelines in Oncology: Lung Cancer273
Table 1. Demographics
Variable With Follow-Up Overall
Total number 1,603 2,180
Average age (y) 63.5  6.2 63.1  6.2
Men 56% 53%
Active smokers 48.2% 45.8%
Average cessation
(former smokers) (y)
9.8  9.5 10.1  8.5
Average pack-years 48.6  22.7 48.6  22.2
Percentage with additional
lung cancer risk factor
25.3% 26.2%Screening (version 1.2012), which set positive nodule thresholds
similar to those used in the NLST (4 mm solid, 5 mm nonsolid,
benign at 2-year stability). Recasting the results was performed to
evaluate the resulting frequency of positive ﬁndings, PPV, and
number of false negatives under the new structured reporting system.METHODS
This was a retrospective, single-center study of our experience
with clinical CT lung screening approved by the institutional
review board. We reviewed consecutive, prevalence, clinical
CT lung screening examinations performed at our institution
from January 2012 through May 2014. To qualify for
screening, individuals had to satisfy the NCCN high-risk
criteria for lung cancer, be asymptomatic, have physicianTable 2. Results
Overall (n ¼ 2,180)
Negative/benign (Lung-RADS 1 and 2) 1
Positive (Lung-RADS 3 and 4)
Probably benign (Lung-RADS 3)
Suspicious (Lung-RADS 4)
Clinical follow-up (n ¼ 1,603)
Negative/benign (Lung-RADS 1 and 2)
Positive (Lung-RADS 3 and 4)
Probably benign (Lung-RADS 3)
Suspicious (Lung-RADS 4)
Diagnosed lung cancer
n Positive examination result
n Includes 3 cases of presumed malignancy*
Positive predictive value
Biopsy-proven lung cancer
n Positive examination result
n Excludes 3 cases of presumed malignancy*
Positive predictive value
Note: NCCN ¼ National Comprehensive Cancer Network; NLST ¼ Nationa
*Patients unable to tolerate biopsy were diagnosed with presumed lung can
multidisciplinary consensus.
274orders for CT lung screening, be free of lung cancer for 5
years, and have no known metastatic disease [3,5].
Image Acquisition and Interpretation
All CT lung screening examinations were performed on 64-
row multidetector CT scanners (LightSpeed VCT and Dis-
covery VCT [GE Medical Systems, Milwaukee, Wisconsin];
Somatom Deﬁnition [Siemens AG, Erlangen, Germany]; iCT
[Philips Medical Systems, Andover, Massachusetts]) at 100
kV and 30 to 100 mA depending on the scanner and the
availability of iterative reconstruction software. Axial images
were obtained at 1.25- to 1.5-cm thickness with 50% overlap
and reconstructed with both soft tissue and lung kernels.
Axial maximum-intensity projections (16  2.5 mm) and
coronal and sagittal multiplanar reformatted images were
reconstructed and used for interpretation.
Original image interpretation was performed by radiologists
speciﬁcally trained and credentialed in CT lung screening using
a structured reporting system and the NCCN guidelines nodule
follow-up algorithms [3,5]. Positive results required the identi-
ﬁcation of a solid, noncalciﬁed nodule 4 mm or a nonsolid
nodule 5 mm for which >2-year stability had not been
established [5].
Application of ACR Lung-RADS
Studies positive for solid nodules <6 mm, nonsolid nodules <2
cm, and positive nodules stable for >3 months but <2 years
were recategorized as benign to estimate the hypothetical ACRPositive Thresholds
NCCN Version 1.2012
(wNLST) ACR Lung-RADS
,579 72.4% 1,949 89.4%
601 27.6% 231 10.6%
508 23.3% 138 6.3%
93 4.3% 93 4.3%
1,185 73.9% 1,435 89.5%
418 26.1% 168 10.5%
352 22.0% 102 6.4%
66 4.1% 66 4.1%
29 (1.8%) 29 (1.8%)
6.9% 17.3%
26 (1.6%) 26 (1.6%)
6.2% 15.5%
l Lung Screening Trial.
cer on the basis of positive results on PET, suspicious growth rate, and
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Table 3. Diagnosed malignancies
Patient ACR Lung-RADS Category Baseline Size (mm) Time to Diagnosis (mo) Histology
1 4 13  14 2 Adenocarcinoma
2 4 15  17 1.5 Squamous cell carcinoma
3 4 9e10 <1 Adenocarcinoma
4 4 10e11 3.5 Presumed adenocarcinoma*
5 4 70  90 <1 Squamous cell carcinoma
6 4 14  18 5.5 Adenocarcinoma
7 4 22  48 1 Carcinoid tumor
8 4 20  20 2 Squamous cell carcinoma
9 4 22  33 1 Adenocarcinoma
10 4 12  19 <1 Adenocarcinoma
11 4 13  17 <1 Adenocarcinoma
12 4 23  29 3 Adenocarcinoma
13 4 Other† 8 Adenocarcinoma
14 3 6e7 12 Squamous cell carcinoma
15 4 8  11 3 Adenocarcinoma
16 4 10e11 4 Squamous cell carcinoma
17 4 39  45 2.5 Squamous cell carcinoma
18 4 6e7 6.5 Squamous cell carcinoma
19 4 26  31 1.5 Adenocarcinoma
20 4 11e12 2 Adenocarcinoma
21 4 Other† 2 Adenocarcinoma
22 4 9  17 3 Squamous cell carcinoma
23 4 11  18 6.5 Presumed adenocarcinoma*
24 3 6e7 8.5 Presumed adenocarcinoma*
25 3 6e7 3 Adenocarcinoma
26 4 36  36 <1 Small cell lung cancer
27 3 7e8 10 Adenocarcinoma
28 4 13  16 1.5 Adenocarcinoma
29 4 33  63 2 Adenocarcinoma
*Patients unable to tolerate biopsy were diagnosed with presumed lung cancer on the basis of positive results on PET, suspicious growth rate, and
multidisciplinary consensus.
†Other ﬁndings included pleural nodularity or thickening not amenable to discrete measurement.Lung-RADS positive rate and PPV in our cohort. Cases
reclassiﬁed as benign would be considered false negative if cancer
was diagnosed within 12 months of the baseline examination.
For both ACR Lung-RADS and the original interpreta-
tion, solid and part-solid nodules >8 mm, growing nodules,
and nonsolid nodules with growing solid components were
categorized as “suspicious.” All other positive nodules were
categorized as “probably benign.” Mediastinal and hilar lymph
nodes measuring >1 cm in the short axis in the absence of
pulmonary nodules and ﬁndings suspicious for infection or
inﬂammation (most commonly areas of tree-in-bud nod-
ularity) not currently considered positive under ACR Lung-
RADS were treated as incidental ﬁndings under both schemas.RESULTS
From January 2012 through May 2014, a total of 2,180 high-
risk patients underwent clinical prevalence CT lung screening
examinations (Table 1). Five hundred seventy-seven of these
2,180 (26%) were patients from outside our institution forJournal of the American College of Radiology
McKee, Regis, McKee n Lung-RADS in Clinical CT Lung Screeningwhom clinical follow-up after the prevalence CT lung screening
examination was not available during this retrospective review.
Application of ACR Lung-RADS had the following impact in
our speciﬁc patient cohort.
Nodule Reclassiﬁcation
Three hundred seventy of 2,180 examinations (17.0%) were
reclassiﬁed as benign, thus decreasing the overall positive rate
from 27.6% to 10.6% (Table 2). Breaking down these
reclassiﬁed cases further, 86% of these (319 of 370) were
originally positive for solid or part-solid nodules between 4 and
6 mm. Notably, all 49 cases originally positive for nonsolid
nodules were downgraded to benign under ACR Lung-RADS.
Lung Cancer Detection Rate
Twenty-nine lung cancers were diagnosed in patients with
positive baseline screening results among the 1,603 patients
with clinical follow-up (average, 480 days). All diagnosed
cancers were solid or part solid at baseline screening, and all275
were positive under ACR Lung-RADS (Table 3). No false
negatives were found in the 152 of 250 cases (61%) reclassiﬁed
as benign with 12-month follow-up.
PPV
ACR Lung-RADS increased the total PPV of the baseline CT
lung screening examination by a factor of 2.5, from 6.9% (29
of 418) to 17.3% (29 of 168) (Table 2). Twenty-ﬁve of 29
cancers (86.3%) were Lung-RADS 4 “suspicious” at baseline
screening, for a Lung-RADS 4 PPV of 37.9%. Excluding the 3
cases of presumed malignancy in patients unable to tolerate
biopsy (and subsequently treated with stereotactic body
radiotherapy) decreased the ACR Lung-RADS PPV to 15.5%
(26 of 168).
Ancillary Findings
Mediastinal and/or hilar lymph nodes >1 cm in the short axis
in the absence of pulmonary nodules 4 mm were present in
1.6% of patients and were classiﬁed as incidental ﬁndings. In
the 6.1% of baseline screens (98 of 1,603) with ﬁndings sus-
picious for infection or inﬂammation, 1 cancer (small cell
histology) was detected within 12 months.DISCUSSION
No false negatives were detected in those patients of our cohort
in whom positive ﬁndings were reclassiﬁed as benign when
applying ACR Lung-RADS. This observation supports the
notion that it is safe to follow solid nodules <6 mm and
nonsolid nodules<20 mm in high-risk patients with annual CT
surveillance. Our evaluation is limited by the relatively small
number of patients reclassiﬁed as benign with 12-month
follow-up (n ¼ 152), from which we would expect to yield
only 0.8 false negatives given the 0.5% PPV of these nodules in
the NLST [1]. The apparent low likelihood of cancer in this
group does suggest that the approach of following 4 to 6 mm
solid pulmonary nodules incidentally found in lower risk pa-
tients (not meeting criteria for CT lung screening) 12 months
after initial discovery is reasonable.
When we applied the ACR Lung-RADS positive thresh-
olds to our study cohort, it reduced our positive clinical CT
lung screening rate to a level similar to that reported at 6 mm
by the International Early Lung Cancer Action Program [2].
Our relative increase in PPV with ACR Lung-RADS (2.5)
was greater than we calculated would have occurred in the
NLST at a 6-mm threshold (1.8), which in part results from
only increasing the positive threshold for solid nodules in our
NLST analysis. Also contributing are differences in the method
of nodule measurement used by the NLST (maximum
dimension) and the NCCN and ACR Lung-RADS (mean
dimension) [3,4].
In the 1.6% of baseline screens with isolated mediastinal or
hilar lymph nodes >1 cm, we observed no cases of malignancy.276Should isolated mediastinal or hilar lymph nodes >1 cm be
classiﬁed as “probably benign” (Lung-RADS 3) and/or “suspi-
cious” (Lung-RADS 4) in a future revision of ACR Lung-
RADS, we would expect an increase in the positive rate by
1.6% to 12.1%, which would decrease our estimated PPV to
15.5% for diagnosed malignancy and 13.8% for pathology
proven cancers.
Isolated ﬁndings suspicious for infection or inﬂammation
had a low predictive value for malignancy of 1% (1 of 98). The
single case of cancer within this group was small cell carcinoma
diagnosed approximately 6 months after the baseline screening.
Small cell carcinoma was overrepresented in interval cancers at
baseline screening in the NLST (4 of 18), likely because of its
central location and rapid doubling time that does not lend itself
to detection with annual CT lung screening [1]. As such, the
occurrence of a case of small cell cancer is not a clear indication
that this group is at sufﬁcient risk to warrant a positive CT lung
screening designation.TAKE-HOME POINTSn Applying ACR Lung-RADS increased the PPV of our
baseline clinical CT lung screening examinations by a
factor of 2.5 compared with using NLST positive
thresholds, without creating additional false negatives.
n ACR Lung-RADS should increase the cost-effectiveness
of CT lung screening by secondarily decreasing the
number of interval scans recommended and performed.
n ACR Lung-RADS virtually eliminates CT lung
screening examinations positive for nonsolid nodules.
n Given the low likelihood of cancer in high-risk pa-
tients with nodules 4 to 6 mm in size, following
incidental solid pulmonary nodules of this size in
lower risk patients (not meeting criteria for CT lung
screening) in <12 months may be unnecessary.REFERENCES
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